Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK AWP settlement

Executive Summary

GlaxoSmithKline settles average wholesale price class action litigation for $70 mil., the company announces Aug. 10. Plaintiffs alleged that GSK inflated certain AWPs - primarily for antiemetics Zofran and Kytril. The settlement, which covers all claims filed in Boston federal court, resolves most of the AWP litigation pending against GSK, company says. GSK reached civil settlements with six state attorneys general as part of a September settlement with the Department of Justice over Zofran and Kytril pricing (1"The Pink Sheet" Sept. 26, 2005, p. 6). Reportedly, there are more than a dozen remaining defendants involved in the AWP litigation, including AstraZeneca and Bristol-Myers Squibb...

You may also be interested in...

GSK’s AWP Pricing Settlement Includes Expanded Training Of Sales Reps

GlaxoSmithKline's $150 mil. settlement with the Department of Justice requires the company to expand its compliance training for its sales reps

Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch

The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.

Sandoz Pledges Price Stability Amid Coronavirus

Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts